4-[3-(5,8-difluoroquinolin-4-yl)-7-(5-methyl-1H-1,2,4-triazol-3-yl)-2-propylbenzimidazol-5-yl]morpholine
C26H25F2N7O — CID 134371754
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[3-(5,8-difluoroquinolin-4-yl)-7-(5-methyl-1H-1,2,4-triazol-3-yl)-2-propylbenzimidazol-5-yl]morpholine
4-[3-(5,8-difluoroquinolin-4-yl)-7-(5-methyl-1H-1,2,4-triazol-3-yl)-2-propylbenzimidazol-5-yl]morpholine (PubChem CID 134371754) has the molecular formula C26H25F2N7O and a molecular weight of 489.53 g/mol. Its IUPAC name is 4-[3-(5,8-difluoroquinolin-4-yl)-7-(5-methyl-1H-1,2,4-triazol-3-yl)-2-propylbenzimidazol-5-yl]morpholine.
Molecular Properties
| Compound Name | 4-[3-(5,8-difluoroquinolin-4-yl)-7-(5-methyl-1H-1,2,4-triazol-3-yl)-2-propylbenzimidazol-5-yl]morpholine |
|---|---|
| PubChem CID | 134371754 |
| Molecular Formula | C26H25F2N7O |
| Molecular Weight | 489.53 g/mol |
| Exact Mass | 489.21 |
| IUPAC Name | 4-[3-(5,8-difluoroquinolin-4-yl)-7-(5-methyl-1H-1,2,4-triazol-3-yl)-2-propylbenzimidazol-5-yl]morpholine |
| SMILES | CCCc1nc2c(-c3n[nH]c(C)n3)cc(N3CCOCC3)cc2n1-c1ccnc2c(F)ccc(F)c12 |
| InChI | InChI=1S/C26H25F2N7O/c1-3-4-22-31-24-17(26-30-15(2)32-33-26)13-16(34-9-11-36-12-10-34)14-21(24)35(22)20-7-8-29-25-19(28)6-5-18(27)23(20)25/h5-8,13-14H,3-4,9-12H2,1-2H3,(H,30,32,33) |
| InChIKey | ZNOWTQYSPDDFOS-UHFFFAOYSA-N |
| XLogP | 4.73 |
| TPSA | 84.75 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 489.53 |
| LogP ≤ 5 | 4.73 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 134371754 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.